OUP user menu

Exposure to paracetamol and asthma symptoms

Francisco Javier Gonzalez-Barcala, Sonia Pertega, Teresa Perez Castro, Manuel Sampedro, Juan Sanchez Lastres, Miguel Angel San Jose Gonzalez, Luis Bamonde, Luciano Garnelo, Luis Valdes, Jose-M Carreira, Jose Moure, Angel Lopez Silvarrey
DOI: http://dx.doi.org/10.1093/eurpub/cks061 706-710 First published online: 29 May 2012


Background: Paracetamol is one of the factors that have been associated with the observed increase in asthma prevalence in the last few years. The influence of environmental or genetic factors in this disease may be different in some countries than in others. The purpose of this study was to analyse the relationship between the paracetamol consumption and asthma prevalence in our community. Methods: A cross-sectional study was conducted on more than 20 000 children and adolescents in Galicia, Spain. The International Study of Asthma and Allergies in Childhood methodology was used to collect the information on asthma symptoms in children, paracetamol consumption, body mass index (BMI), pets in the home, education level of the mother and parental asthma and smoking habits. The influence of paracetamol consumption on the prevalence of asthma symptoms was calculated using logistic regression, adjusted for the other parameters included in the study. Results: After adjusting for gender, BMI, having a cat or dog, maternal education, parental asthma and smoking, in 6- to7-year-old children, the consumption of paracetamol during the first year of life is associated with asthma [odds ratio (OR) 2.04 (1.79–2.31) for wheezing at some time]. Paracetamol consumption in the previous year leads to a significant increase in the probability of wheezing at some time [OR 3.32 (2.51–4.41)] in young children and adolescents [OR 2.12 (1.68–2.67)]. Conclusions: Paracetamol consumption is associated with a significant increase in asthma symptoms. The effect is greater the more often the drug is taken.


An increase in the prevalence of childhood asthma has been observed over the last few years.1 At the same time, paracetamol has become the most used treatment for fever in the child. Given that the use of antipyretics is common, even when there is minimal or no fever, ∼75% of children in Western countries are treated with paracetamol.2,3

Various studies appear to support some effect of paracetamol on the increase in asthma prevalence.4–6

However, other studies show discrepant results, with no relationship being observed between paracetamol consumption and asthma.7,8

The purpose of this study was to evaluate the relationship between paracetamol consumption and asthma symptoms in our population.


We performed a multicentre study using the methodology of the International Study of Asthma and Allergies in Childhood (ISAAC; http://isaac.auckland.ac.nz). Written questionnaires, previously translated and validated in Spanish, were used in this study.9,10

The target population of the study was all those school children aged 6–7 years and 13–14 years from six of the main health catchment areas of Galicia, which includes a total of 1.9 million inhabitants (69% of the population in this autonomous region).

At these ages, schooling is mandatory by law, thus it can be assumed that the schooling rate is quite close to 100%.

Following the ISAAC protocol, a minimum sample size of 1000 valid questionnaires was established, for each age group and each area studied, to obtain the levels of prevalence and also to detect the possible differences between the areas analysed.11

The schools required from each health area were randomly selected, and all children in the targeted age ranges were included. The schools that refused to take part in the study were replaced with others.

The field work was done between October 2006 and February 2007.

Permission was sought from parents or guardians, who also answered the questionnaires in the 6–7 years age group, whereas in the older age group, the responses to the questionnaires were made by the children themselves.

The questionnaire data were introduced manually into a data base, using double entry with subsequent validation, in accordance with the ISAAC protocols.

The environmental questionnaire included questions about consumption of certain foods in the past 12 months, asthma symptoms, self-reported height and weight, parental asthma, exposure to pets, smoking habits of parents and mother’s education level.

Paracetamol consumption in the past year was evaluated based on the response to the question: ‘How often have you taken paracetamol in the last 12 months?’ for 13- to 14-year olds and ‘How often have you given your child paracetamol in the last 12 months?’ for 6- to 7-year-old children, with three response options: (i) never; (ii) at least once a year; and (iii) at least once a month. In younger children, it also asked about the consumption of paracetamol in the first year of life, with the question: ‘In the first 12 months of life of your child, did you regularly give him/her paracetamol?’ with two response options, yes or no.11 The five brands of paracetamol most frequently consumed in our country are specifically mentioned in the questionnaire.

Obesity and overweight were defined in accordance with the body mass index (BMI) cut-off points mentioned by Cole et al.12 for each age group and sex.

The educational level of the mother was classified into three categories: (i) no education or only primary school education; (ii) secondary school education; and (iii) university education.

For each child, we established four mutually exclusive categories of passive smoking: neither parent smoked, the father only, the mother only and both.

Two categories were established in accordance with parental asthma: if the father or the mother had asthma, or if neither parent had asthma.

The presence of a dog or cat in the home was classified based on the questionnaire questions corresponding to having a cat or dog in the home during the first year of life or during the past year.

For the purpose of this study, wheezing ever was defined as a positive answer to the question: ‘Has your child ever had wheezing or whistling in the chest at any time in the past?’

Current asthma was defined as a positive answer to the question: ‘Has your child had wheezing or whistling in the chest during the last 12 months?’

Severe asthma was defined as a combination of the three questions assessing the severity of asthma: ‘How many attacks of wheezing has your child had during the last 12 months? (none, 1–3, 4–12, >12)’, ‘In the last 12 months, how often, on average, has your child’s sleep been disturbed as a result of wheezing? (never, <1 night/week, ≥1 nights/week)’ and ‘In the last 12 months, has wheezing ever been severe enough to limit your child’s speech to only one or two words at a time between breaths?’. Children were considered to have severe asthma when there were ≥4 asthma attacks or when sleep was disturbed ≥1 nights/week or when there had been an episode of speech limitation.13

Exercise induced asthma was defined as a positive answer to the question: ‘In the last 12 months, has your child's chest sounded wheezy during or after exercise?9,14

Data analysis

We used multiple logistic regression to obtain adjusted prevalence odds ratios (ORs) and 95% confidence intervals (95% CIs) between asthma symptoms of the school children and paracetamol consumption. Therefore, we considered those children as ‘control group’ who mentioned not taking paracetamol. These calculations were preferred to other methods (e.g. linear regression) which do not provide information on risk increase and require statistical assumptions (like linearity) that are unverifiable in empirical conditions.

In the multivariate analysis, the results presented are adjusted for parental smoking habits, parental asthma, maternal education level, cat and dog exposure, adherence to Mediterranean diet and obesity of the children. The children with incomplete data were excluded from the study. The statistical analysis was performed using SPSS 17.0 software. The study was approved by the Clinical Research Ethics Committee of Galicia.


A total of 10 371 children were included in the 6- to 7-year-old group (response rate 72.4%). The participation rate was 84.4% in the 13- to 14-year-old group, which included 10 372 children (table 1).

View this table:
Table 1

Prevalence of asthma symptoms

6–7 years13–14 years
N (%)N (%)
Wheezing ever
    No6519 (61.0)8262 (77.0)
    Yes4171 (39.0)2468 (23.0)
Current asthma
    No9249 (86.5)9319 (86.8)
    Yes1441 (13.5)1411 (13.2)
Exercise induced asthma
    No10 010 (93.6)8585 (80.0)
    Yes680 (6.4)2145 (20.0)
Severe asthma
    No10 170 (95.1)10 106 (94.2)
    Yes520 (4.9)624 (5.8)
  • All values as number of cases (N) and %.

The general characteristics of the children, parental asthma, parental smoking, maternal education level, cat and dog exposure and paracetamol use are shown in table 2.

The prevalence of asthma in the lower age group was 39.0%, whereas that of current asthma was 13.5%, severe asthma 4.9% and exercise induced asthma 6.4%. In 13- to 14-year olds, these prevalences were 23.0, 13.2, 5.8 and 20.0%, respectively (table 1). More than 50% of the children had a parent who smoked (table 2).

Only 23% of the adolescents (13- to 14-year olds) and 13% of the children stated that they had not taken paracetamol in the previous year. In regard to the first year of life, 48.6% of the children had not been given it (table 2).

All the asthma symptoms analysed increased significantly with paracetamol consumption. The effects appear stronger in 6- to 7-year-old children, where the taking of paracetamol at least once a month in the last year is associated with a five times more probability of having asthma symptoms, compared with those children who had never taken paracetamol. For current asthma, an OR is 5.42 with 95% CI of 3.68–7.99 and for severe asthma, an OR is 5.36 with 95% CI 2.79–10.27 (table 3). In the same age group, on analysing the paracetamol consumption in the first year of life, the highest risk increase with consumption of the drug is observed for ‘wheezing ever’, with an OR of 2.04 with 95% CI of 1.79–2.31 (table 3).

View this table:
Table 2

Main characteristics of the children and prevalence of risk factors

6–7 years13–14 years
N (%)N (%)
    Male5321 (50.2)5269 (49.7)
    Female5270 (49.8)5323 (50.3)
    Normal weight5261 (67.0)7421 (82.3)
    Overweight1834 (17.2)1396 (15.5)
    Obesity752 (9.6)197 (2.2)
Having cat in the past 12 months
    No9699 (92.6)8903 (83.8)
    Yes773 (7.4)1722 (16.2)
Having cat in the first year of life
    No10 026 (94.5)6730 (88.4)
    Yes584 (5.5)879 (11.6)
Having dog in the past 12 months
    No9111 (87.4)7563 (71.3)
    Yes1313 (12.6)3050 (28.7)
Having dog in the first year of life
    No9457 (89.4)6060 (79.5)
    Yes1123 (10.6)1559 (14.5)
Maternal education
    No education/elementary2981 (28.4)2261 (22.1)
    High school4012 (37.5)4418 (43.2)
    University3519 (32.9)3553 (34.7)
Parental asthma
    Neither parent asthma5507 (87.2)5078 (90.0)
    Some parent asthma806 (12.8)566 (10.0)
Parental smoking
    Neither parent smoke5020 (48.7)5057 (48.4)
    Father only1941 (18.8)1893 (18.1)
    Mother only1354 (13.1)1487 (14.2)
    Both parents1999 (19.4)2016 (19.3)
Paracetamol use in the first year of life
    No5058 (48.6)NA (NA)
    Yes5344 (51.4)NA (NA)
Paracetamol use in the last year
    Never1323 (12.8)2422 (23.4)
    At least once a year8117 (78.6)5440 (52.6)
    At least once per month893 (8.6)2485 (24.0)
  • All values as number of cases (N) and %. NA, not applicable (there is not data).

View this table:
Table 3

Odds ratio for prevalence of asthma symptoms according to paracetamol use in children aged 6–7

Wheezing everCurrent asthmaExercise induced asthmaSevere asthma
Paracetamol use In the first year of lifeOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
    Yes2.04 (1.79–2.31)1.66 (1.38–1.99)1.52 (1.16–1.99)1.82 (1.32–2.53)
In the last year
    At least once a year1.45 (1.20–1.76)1.71 (1.24–2.37)1.68 (1.03–2.73)1.64 (0.91–2.94)
    At least once per month3.32 (2.51–4.41)5.42 (3.68–7.99)5.26 (3.03–9.15)5.36 (2.79–10.27)
  • Adjusted by gender, body mass index, having cat and dog, maternal education, parental asthma and parental smoking.

View this table:
Table 4

Odds ratio for prevalence of asthma symptoms according to paracetamol use in children aged 13–14

Wheezing everCurrent asthmaExercise induced asthmaSevere asthma
Paracetamol use In the last yearOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
    At least once a year1.41 (1.15–1.73)1.40 (1.07–1.85)1.43 (1.15–1.78)1.34 (0.87–2.06)
    At least once per month2.12 (1.68–2.67)2.51 (1.87–3.39)2.40 (1.88–3.06)3.31 (2.13–5.14)
  • OR, odds ratio; CI, confidence interval.

  • Adjusted by gender, body mass index, having cat and dog, maternal education, parental asthma and smoking.

In the adolescents, paracetamol consumption at least once in the past year is associated with an increase of 43% in the prevalence of exercise induced asthma, OR: 1.43 (95% CI: 1.15–1.78) (table 4). When paracetamol is taken once a month, the effect is greater, with an OR between 2.12 (95% CI: 1.68–2.67) for wheezing ever, and 3.31 (95% CI: 2.13–5.14) for severe asthma (table 4).


The results obtained in this study seem to support a relationship between paracetamol consumption and an increase in asthma prevalence. The effect could also be dose dependent, as taking paracetamol more often is associated with a higher increase in the probability of presenting with asthma symptoms.

These results are in agreement with those presented in the majority of publications have analysed this relationship.

Thus, in a recent meta-analysis, Etminan et al.4 observed a significant increase in the risk of asthma with exposure to paracetamol (OR: 1.60; 95% CI: 1.48–1.74).4

Furthermore, various prospective studies, where the exposure precedes the result, seem to associate the use of paracetamol with asthma in both children and adults. A study conducted in Ethiopia with more than 1000 children evaluated at 3 years old, the use of paracetamol was associated with a higher presence of wheezing, which was also dose dependent, adjusted for respiratory infections and other factors, since with the ingestion of 1–3 tablets of paracetamol per month, the increase in wheezing is not significant (OR: 1.77, 95% CI: 0.96–3.26), but with the consumption of four or more tablets per month, the OR: 6.78 with a 95% CI: 1.89–24.39.15 In another British study, more than 11 000 children were studied prospectively. The taking of paracetamol in the first 6 months of life of the child was associated with a higher asthma prevalence (OR: 1.11, 95% CI: 1.00–1.23) and wheezing (OR: 1.12, 95% CI: 1.00–1.25), adjusted for infections and other confounding factors.16

In the Nurses Health Study in the USA, it was observed that the use of paracetamol more than 14 days a month was associated with a higher asthma incidence (OR: 1.63, 95% CI: 1.1–2.39).17

In another Danish study, a more frequent use of paracetamol was associated with a higher prevalence of adult-onset asthma (OR: 2.99, 95% CI: 1.44–6.20).18

Other cross-sectional studies give similar conclusions. In a study including more than 200 000 children from 73 centres in 31 countries, higher paracetamol consumption was associated with a higher prevalence of allergic diseases, such as asthma (OR: 3.23, 95% CI: 2.91–3.60) or rhinitis.19

In adolescents, the exposure to paracetamol in the previous year was associated with a higher asthma prevalence, adjusted for other co-factors. The risk of current asthma symptoms increases depending on the dose (OR: 1.43, 95% CI: 1.33–1.53 for medium use vs. no use and OR: 2.51, 95% CI: 2.33–2.70 for high use vs. no use). The study included more than 300 000 adolescents, from 50 countries, using the methodology of the ISAAC study. The relationship was dose dependent.6

In a multicentre Canadian study, using the ISAAC methodology, significant differences between different centres were observed in asthma prevalences, as well as in the use of paracetamol, in 13- to 14-year-old adolescents. In the multivariate analysis, paracetamol intake at least once a month showed an increase in current wheezing (OR: 1.92, CI 95%: 1.71–2.17) compared with acetaminophen used less than once a month.20

An increase in asthma associated with taking paracetamol more often was also observed in young adults (20–44 years) from 12 European populations (OR: 2.87, 95% CI: 1.49–5.37).5

In other studies where the effect of paracetamol is analysed in comparison with other drugs, they appear to reinforce the effect of paracetamol for the increase in asthma.

A randomized study on children in Boston, USA, obtained a lower asthma risk when ibuprofen rather than paracetamol was taken. Compared with children who were assigned to receive acetaminophen, the relative risk estimate of outpatient visits for asthma for those assigned to ibuprofen was 0.56 (95% CI: 0.34–0.95) after adjusting for age, gender and race. A placebo group was not used in this study, which meant it could not be determined whether the results depended on ibuprofen being a protector, or paracetamol a risk factor.21

In a Danish study, pregnant women treated more often with paracetamol had children with a higher risk of hospitalization for asthma (OR: 1.24, 95% CI: 1.11–1.38). The fact that the main indication for taking the drug was pain and not fever, as well as similar effects not being seen with other analgesics, seems to support a real effect of paracetamol, and not a confounding effect, as could be the case if the indication was for respiratory infections.22

However, other authors did not observe any relationship between paracetamol use and asthma.7,8 Some methodological weaknesses were observed in these studies.

In a study with Norwegian children, no relationship was found between the use of paracetamol by the mother during pregnancy, nor by boys in the first 6 months of life who had asthma at 10 years old, although they did find a relationship between the higher use of paracetamol and a history of asthma in the girls. The study by Bakkeheim included few children who were given paracetamol in the first 6 months of life (83 children, which was 8% of the sample included), with no data on subsequent paracetamol consumption and the asthma assessed at 10 years.8 In other studies with Western populations, the prevalence of taking paracetamol in the first year of life generally exceed 50%.7,23,24

The study by Lowe et al., was a prospective study that analysed the relationship between treatment with paracetamol in the first 2 years of life and the presence of asthma at 7 years. This relationship disappeared if it was considered that the paracetamol was taken for non-respiratory diseases, while it remained if it was considered that the patients were given paracetamol for a respiratory disease. This seemed to suggest a confounding effect of the respiratory infection, more than an effect of the paracetamol itself.7 A weakness of this study was that it only evaluated the administration of paracetamol between 0 and 2 years, but not that currently or recently. Another weakness was that the number of children treated with paracetamol for diseases other than respiratory was limited, although it did not specify the total figure, 495 children completed the follow up, and of these 88.7% were treated for an upper airway infection, which would leave about 63 children treated with paracetamol for a non-respiratory disease.7

Furthermore, various pathophysiological mechanisms are known that could explain this relationship.

On one hand, paracetamol has been shown to dose dependently reduce lung and serum glutathione concentrations in lungs and blood.25,26 Antioxidant activity is reduced on reducing the glutathione levels. This may lead to tissue damage, smooth muscle contraction, bronchial hyperresponsiveness, increase in vascular patency, release of inflammatory mediators and interfere with the activity of beta receptors.27

The depletion of glutathione also reduces the levels of Th1 cytokinases favouring the predominance of Th2.27

Another possible mechanism is, that on reducing the fever, the levels of cytokinases released during febrile episodes, which are mainly Th1, are reduced as such that they also lead to a predominance of Th2.27

High doses of paracetamol are cytotoxic for pneumocytes and can cause acute lung damage.28Paracetamol also has a modulating effect on the activity of myeloperoxidase, an enzyme that takes part in various oxidation mechanisms.29

It has been demonstrated in animal models that the activation of transient receptor potential ankyrin-1 receptor by paracetamol metabolites induces inflammatory activity in the lung, with an increase in the number of neutrophils, myeloperoxidase activity and cytokinase levels.30

A possible antigenic effect of paracetamol has also been described, with an increase in histamine and IgE.31

Our study has some limitations. On one hand, on being a cross-sectional study, a causal relationship cannot be established.

On the other hand, the possibility of ‘inverse causality’ must be considered, as children with asthma had a higher tendency for respiratory infections and thus, a higher use of paracetamol.32 But this should not influence the prevalence of eczema, which was also increased in children who took more paracetamol.6,19

There could have been a memory bias, since the taking of paracetamol would be remembered better by those children who had more, or more severe, episodes of infections, and this higher frequency or severity of respiratory infections could be favoured as a result of being asthmatics.33,34

Given the range of the randomly selected population sample included, and the application of extensively validated methodology, the findings of our study seem to support some relationship between paracetamol consumption and asthma symptoms in our population.


This work was funded by the Maria Jose Jove Foundation.

Conflicts of interest: None declared.

Key points

  • Paracetamol consumption is associated with a significant increase in asthma symptoms.

  • The effect is greater the more often the drug is taken.

  • The effects appear stronger in children than in adolescents.


View Abstract